Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE
BJU Int. 2012 110 (11 Pt B): E721-6

PMID: 23016517 · DOI:10.1111/j.1464-410X.2012.11536.x

MeSH Terms (20)

Aged Androgen Antagonists Antineoplastic Agents Disease-Free Survival Docetaxel Dose-Response Relationship, Drug Follow-Up Studies Gonadotropin-Releasing Hormone Humans Male Middle Aged Neoplasm Staging Prospective Studies Prostate-Specific Antigen Prostatic Neoplasms Radiation-Sensitizing Agents Radiotherapy, Intensity-Modulated Radiotherapy Dosage Taxoids Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: